Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Theranostic platform for early diagnosis and treatment of cancer based on Acoustofluidics

Descrizione del progetto

Piattaforma microfluidica per l’isolamento delle vescicole tumorali

Le vescicole extracellulari (extracellular vesicles, EV) sono particelle di dimensioni nanometriche rilasciate dalle cellule per comunicare con l’ambiente circostante. Il loro carico molecolare riflette lo stato e l'origine delle cellule progenitrici, rendendo le EV biomarcatori molto promettenti per la diagnosi precoce del cancro e la terapia. Tuttavia, gli attuali metodi di isolamento delle EV sono lenti, richiedono grandi volumi di campione e spesso mancano di purezza, limitandone l’uso clinico. Il progetto TheraSonic, finanziato dal CER, affronta questa sfida modellando e sviluppando sistemi microfluidici per arricchire le EV da quantità di microlitri di fluidi corporei o campioni derivati da tumori. Questi sistemi mirano a fornire un arricchimento ad alto rendimento, scalabile e altamente selettivo di frazioni specifiche di EV, gettando le basi per una diagnostica personalizzata del cancro e per futuri approcci terapeutici basati sulle EV.

Obiettivo

This proposal develops a pioneering microscale ultrasound-based system to enrich extracellular vesicles (EVs) from µL volumes of whole blood and cancer spheroids, targeting early cancer detection and revolutionizing therapeutic approaches.

EVs, nanoscale particles (30-1000 nm) released by mammalian cells, hold potential as biomarkers for cancer detection and as drug delivery vehicles due to their cell-specific cargo and ability to penetrate cell membranes. However, current isolation methods like centrifugation are time-consuming, require large sample volumes, and lack purity and scalability, limiting clinical application, particularly in high-throughput biomarker discovery and therapeutic development.

I propose to overcome these critical barriers through the creation of TheraSonic, a disruptive acoustic force-based microfluidic platform that leverages a novel particle trapping effect in bulk volumes. TheraSonic will enable the unprecedented enrichment of EVs from µL biofluid samples, offering transformative improvements in purity, scalability, and throughput. By integrating spheroid culturing and multi-omics, this platform will reveal insights into cancer heterogeneity.

Moreover, TheraSonic uniquely enables the selective isolation of EV subpopulations based on size, surface markers, and acoustic properties. This unprecedented resolution will uncover highly specific cancer vesicle profiles that current methods fail to detect, leading to the discovery of highly sensitive and specific cancer biomarkers.

The scalable nature of the platform will be harnessed to significantly increase capacity and throughput, providing needed EV material for novel autologous EV therapies. Combined with organ-on-a-chip technologies, it will facilitate the development of individualised cancer treatments on an unmatched scale.

In summary, TheraSonic represents a disruptive innovation that will induce a paradigm shift in EV enrichment, profoundly impacting cancer research and treatment.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-STG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Contributo netto dell'UE
€ 1 499 726,00
Indirizzo
SEMINARSTRASSE 2
69117 Heidelberg
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 499 726,00

Beneficiari (1)